Advanced epithelial ovarian cancer: From standard chemotherapy to promising molecular pathway targets - Where are we now?

Anticancer Research

Volumn 34, Issue 5, 2014, Pages 2069-2078

  Syrios, John ^a   Banerjee, Susana ^a   Kaye, Stanley B ^a  

^a INSTITUTE OF CANCER RESEARCH   (United Kingdom)

Author keywords

Conventional chemotherapy; Epithelial ovarian cancer; Histological subtypes; Molecular pathway targets; PARP inhibitors; Review; Tumour angiogenesis; Tyrosine kinase inhibitors

Indexed keywords

ANGIOPOIETIN; BEVACIZUMAB; FOLATE RECEPTOR; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE INHIBITOR; PACLITAXEL; PROTEIN TYROSINE KINASE INHIBITOR; SOMATOMEDIN; ANTINEOPLASTIC AGENT;

ANTIANGIOGENIC ACTIVITY; BREAST CANCER; CANCER CELL; CANCER CHEMOTHERAPY; CANCER RECURRENCE; CANCER RESISTANCE; CAUSE OF DEATH; CELL CYCLE CHECKPOINT; CHEMOSENSITIVITY; FEMALE; GENE MUTATION; HISTOPATHOLOGY; HOMOLOGOUS RECOMBINATION; HUMAN; NEOPLASM; NEOVASCULARIZATION (PATHOLOGY); OVARY CARCINOMA; PROTEIN TARGETING; REVIEW; SUPPRESSOR GENE; ANIMAL; CONVENTIONAL CHEMOTHERAPY; GENETICS; HISTOLOGICAL SUBTYPES; MOLECULAR PATHWAY TARGETS; OVARY TUMOR; PARP INHIBITORS; TUMOUR ANGIOGENESIS; TYROSINE KINASE INHIBITORS;

CONVENTIONAL CHEMOTHERAPY; EPITHELIAL OVARIAN CANCER; HISTOLOGICAL SUBTYPES; MOLECULAR PATHWAY TARGETS; PARP INHIBITORS; REVIEW; TUMOUR ANGIOGENESIS; TYROSINE KINASE INHIBITORS;

ANIMALS; ANTINEOPLASTIC AGENTS; FEMALE; HUMANS; NEOPLASMS, GLANDULAR AND EPITHELIAL; OVARIAN NEOPLASMS;

EID: 84903146674     PISSN: 02507005     EISSN: 17917530     Source Type: Journal    
DOI: None     Document Type: Review

References (77)

1. Howlader N, Noone AM, Krapcho M et al: SEER Cancer Statistics Review, 1975-2010, National Cancer Institute. Bethesda, MD, http://seer.cancer.gov/csr/1975-2010/, based on November 2012 SEER data submission, posted to the SEER web site, 2013.
2. Du Bois A, Luck HJ, Meier W et al: A randomized clinical trial of cisplatin/paclitaxel versus carboplatin/paclitaxel as first-line treatment of ovarian cancer. J Natl Cancer Inst 95: 1320-1330, 2003.
3. Thigpen T, Dubois A, McAlpine J et al: First-line therapy in ovarian cancer trials. Int J Gynecol Cancer 21: 756-762, 2011.
4. Katsumata N, Yasuda M, Takahashi F et al: Dose-dense paclitaxel once a week in combination with carboplatin every three weeks for advanced ovarian cancer: a phase III, open-label, randomised controlled trial. Lancet 374(9698): 1331-1338, 2009.
5. Katsumata N, Yasuda M, Isonishi S et al: Long-term results of dose-dense paclitaxel and carboplatin versus conventional paclitaxel and carboplatin for treatment of advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer (JGOG 3016): a randomised, controlled, open-label trial. Lancet Oncol 14(10): 1020-1026, 2013.
6. Perren TJ, Swart AM, Pfisterer J et al: A phase III trial of bevacizumab in ovarian cancer. N Engl J Med 365(26): 2484-2496, 2011.
7. Oza A, Perren T, Swart AM et al: ICON7 final overall survival results in the GCIG phase III randomized trial of bevacizumab in women with newly diagnosed ovarian cancer. Program and abstracts of the European Cancer Congress, 2013; September 27-October 1, 2013; Amsterdam, The Netherlands. Abstract LBA6.
8. Burger RA, Brady MD, Bookman MA et al: Incorporation of bevacizumab in the primary treatment of ovarian cancer. N Engl J Med 365(26): 2473-2483, 2011.
9. Randall L, Burger R, Nguyen H et al: Outcome differences in patients with advanced epithelial ovarian, primary peritoneal, and fallopian tube cancers treated with and without Bevacizumab. Presented at the Society for Gynecologic Oncology Annual Meeting on Women's Cancer; March 9-12, 2013, Los Angeles, CA, USA.
10. Kumar R, Knick VB, Rudolph SK et al: Pharmacokinetic-pharmacodynamic correlation from mouse to human with pazopanib, a multikinase angiogenesis inhibitor with potent antitumor and antiangiogenic activity. Mol Cancer Ther 6(7): 2012-2021, 2007.
11. Du Bois A, Floquet A, Kim JW et al: Randomized, double-blind, phase III trial of pazopanib versus placebo in women who have not progressed after first-line chemotherapy for advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer (AEOC): Results of an international Intergroup trial (AGO-OVAR16). J Clin Oncol 31(suppl; LBA 5503), 2013.
12. Du Bois A, Kristensen G, Ray-Coquard I et al: AGO-OVAR 12: A randomized placebo-controlled GCIG/ENGOT-Intergroup phase III trial of standard frontline chemotherapy +/-nintedanib for advanced ovarian cancer. Int J Gynecol Cancer Vol. 23, Issue 8, Supplement 1, 2013.
13. Aghajanian C, Blank SV, Goff BA et al: OCEANS: a randomized, double-blind, placebo-controlled phase III trial of chemotherapy with or withoutbevacizumab in patients with platinum-sensitive recurrent epithelial ovarian, primary peritoneal, or fallopian tube cancer. J Clin Oncol 30(17): 2039-2045, 2012.
14. Pujade-Lauraine E, Hilpert F, Weber B et al: (2012) AURELIA: A randomized phase III trial evaluating bevacizumab (BEV) plus chemotherapy (CT) for platinum (PT)-resistant recurrent ovarian cancer (OC) (LBA5002). J Clin Oncol 30(Suppl. Abstracts): LBA5002, 2012.
15. Witteveen P, Lortholary A, Fehm T et al: Final overall survival (OS) results from AURELIA, an open-label randomised phase III trial of chemotherapy (CT) with or without bevacizumab (BEV) for platinum-resistant recurrent ovarian cancer (OC). Program and abstracts of the European Cancer Congress, September 27-October 1, 2013; Amsterdam, The Netherlands. Abstract LBA 5, 2013.
16. Ledermann JA, Perren T, Raja FA et al: Randomised double-blind phase III trial of cediranib (AZD 2171) in relapsed platinum sensitive ovarian cancer: Results of the ICON6 trial. Program and abstracts of the European Cancer Congress, September 27-October 1, 2013; Amsterdam, The Netherlands. Abstract LBA 10, 2013.
17. ClinicalTrials.gov identifier: NCT01468909.
18. Karlan BY, Oza AM, Richardson GE et al: Randomized, double-blind, placebo-controlled phase II study of AMG 386 combined with weekly paclitaxel in patients with recurrent ovarian cancer. J Clin Oncol 30(4): 362-371, 2012.
19. Monk BJ, Poveda A, Vergote I et al: A phase III, randomized, double-blind trial of weekly paclitaxel plus the angiopoeitin 1 and 2 inhibitor, trebananib, or placebo in women with recurrent ovarian cancer: TRINOVA-1. 17th ECCO-38th ESMO-32nd ESTRO European Cancer Congress. 2013, 1 October during the Gynaecological Cancer Proffered Papers Session (Abstract E17-7107).
20. ClinicalTrials.gov identifier: NCT01281254.
21. Alsop K, Fereday S, Meldrum C et al: BRCA mutation frequency and patterns of treatment response in BRCA mutation-positive women with ovarian cancer: a report from the Australian Ovarian Cancer Study Group. J Clin Oncol 30(21): 2654-2663, 2012.
22. Fong PC, Boss DS, Yap TA et al: Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers. N Engl J Med 361(2): 123-134, 2009.
23. Ashworth A: A synthetic lethal therapeutic approach: poly(ADP) ribose polymerase inhibitors for the treatment of cancers deficient in DNA double-strand break repair. J Clin Oncol 26: 3785-3790, 2008.
24. Gelmon KA, Tischkowitz M, Mackay H et al: Olaparib in patients with recurrent high-grade serous or poorly differentiated ovarian carcinoma or triple-negative breast cancer: a phase II, multicentre, open-label, non-randomised study. Lancet Oncol 12(9): 852-861, 2011.
25. Press JZ, De Luca A, Boyd N et al: Ovarian carcinomas with genetic and epigenetic BRCA1 loss have distinct molecular abnormalities. BMC Cancer 8: 17, 2008.
26. Ledermann JA, Harter P, Gourley C et al: Olaparib maintenance therapy in platinum-sensitive relapsed ovarian cancer. N Engl J Med 366(15): 1382-1392, 2012.
27. Ledermann JA, Harter P, Gourley C et al: Olaparib maintenance therapy in patients with platinum-sensitive relapsed serous ovarian cancer (SOC) and a BRCA mutation (BRCAm). J Clin Oncol 31, (suppl; abstr 5505), 2013.
28. ClinicalTrials.gov Identifier: NCT01844986.
29. ClinicalTrials.gov Identifier: NCT01874353.
30. Sandhu SK, Schelman WR, Wilding G et al: The poly(ADP-ribose) polymerase inhibitor niraparib (MK4827) in BRCA mutation carriers and patients with sporadic cancer: a phase I dose-escalation trial. Lancet Oncol 14(9): 882-892, 2013.
31. ClinicalTrials.gov Identifier: NCT01847274.
32. ClinicalTrials.gov Identifier: NCT01891344.
33. Ramanathan R, Wainberg Z, Mina L et al: PARP inhibition with BMN 673 in ovarian and breast cancer patients with deleterious mutations of BRCA1 and BRCA2. Program and abstracts of the European Cancer Congress, September 27-October 1, 2013; Amsterdam, The Netherlands. Abstract LBA 29, 2013.
34. Oza AM, Cibula D, Benzaquen AO et al: Olaparib plus chemotherapy, followed by maintenance monotherapy, in women with platinum-sensitive recurrent serous ovarian cancer (PSR SOC):BRCA1/2 mutation (BRCAm) and interim overall survival analyses. Program and abstracts of the European Cancer Congress, September 27-October 1, 2013; Amstersdam, The Netherlands. Abstract 3002, 2013.
35. Sessa C. Update on PARP1 inhibitors in ovarian cancer. Ann Oncol 22(Suppl 8): viii72-viii76, 2011.
36. Rehman FL, Lord CJ, Ashworth A. The promise of combining inhibition of PI3K and PARP as cancer therapy. Cancer Discov 2(11): 982-984, 2012.
37. Sherr CJ. Cancer cell cycles. Science 274(5293): 1672-1677, 1996.
38. Nigro JM, Baker SJ, Preisinger AC et al: Mutations in the p53 gene occur in diverse human tumour types. Nature 342(6250): 705-708, 1989.
39. Wang Y, Li J, Booher RN et al: Radiosensitization of p53 Mutant Cells by PD0166285, a Novel G2 Checkpoint Abrogator. Cancer Res 61(22): 8211-8217, 2001.
40. Kreahling JM, Foroutan P, Reed D et al: WEE1 inhibition by MK-1775 leads to tumor inhibition and enhances efficacy of gemcitabine in human sarcomas. PLoS One 8(3): e57523, 2013.
41. Haarberg HE, Paraiso KH, Wood E et al: Inhibition of WEE1, AKT, and CDK4 underlies the efficacy of the HSP90 inhibitor XL888 in an in vivo model of NRAS-mutant melanoma. Mol Cancer Ther 12(6): 901-912, 2013.
42. Russell MR, Levin K, Rader J et al: Combination therapy targeting the Chk1 and Wee1 kinases shows therapeutic efficacy in neuroblastoma. Cancer Res 73(2): 776-784, 2013.
43. Sarcar B, Kahali S, Prabhu AH et al: Targeting radiation-induced G(2) checkpoint activation with the WEE-1 inhibitor MK-1775 in glioblastoma cell lines. Mol Cancer Ther 10(12): 2405-2414, 2011.
44. Rajeshkumar N V, De Oliveira E, Ottenhof N et al: MK-1775, a potent WEE1 inhibitor, synergizes with gemcitabine to achieve tumor regressions, selectively in p53-deficient pancreatic cancer xenografts. Clin Cancer Res 17(9): 2799-2806, 2011.
45. ClinicalTrials.gov Identifier: NCT01357161.
46. Kalli KR, Oberg AL, Keeney GL et al: Folate receptor alpha as a tumor target in epithelial ovarian cancer. Gynecol Oncol 108: 619-626, 2008.
47. Naumann RW, Coleman RL, Burger RA et al: PRECEDENT: A randomized phase II trial comparing vintafolide (EC145) and Pegylated Liposomal Doxorubicin (PLD) in combination versus PLD alone in patients with platinum-resistant ovarian cancer. J Clin Oncol 31(35): 4400-4406, 2013.
48. ClinicalTrials.gov Identifier: NCT01170650.
49. Muller M, Dietel M, Turzynski A and Wiechen K: Antisense phosphorothioate oligodeoxynucleotide down-regulation of the insulin-like growth factor 1 receptor in ovarian cancer Cells. Int J Cancer 77(4): 567-571, 1998.
50. Kurmasheva RT and Houghton PJ: IGF-I mediated survival pathways in normal and malignant cells. Biochim Biophys Acta 1766(1): 1-22, 2006.
51. Pollak M. Insulin and insulin-like growth factor signaling in neoplasia. Nature Rev Cancer 8: 915-928, 2008.
52. Lu L, Katsaros D, Wiley A et al: The relationship of insulin like growth factor-II, insulin-like growth factor binding protein-3, and estrogen receptor-Alpha expression to disease progression in epithelial ovarian cancer. Clin Cancer Res 12(4): 1208-1214, 2006.
53. Sayer R, Lancaster JM, Pittman J et al: High insulin-like growth factor-2 (IGF-2) gene expression is an independent predictor of poor survival for patients with advanced-stage serous epithelial ovarian cancer. Gynecol Oncol 96(2): 355-361, 2005.
54. Harb WA, Sessa C, Hirte HW et al: A phase I study evaluating the combination of OSI-906, a dual inhibitor of insulin growth factor-1 receptor (IGF-1R) and insulin receptor (IR) with weekly paclitaxel (PAC) in patients with advanced solid tumors. J Clin Oncol (Meeting Abstracts) 29(Suppl No15): 3099, 2011.
55. ClinicalTrials.gov Identifier: NCT00889382.
56. Pohl G, Ho CL, Kurman RJ et al: Inactivation of the mitogen-Activated protein kinase pathway as a potential target-based therapy in ovarian serous tumors with KRAS or BRAF mutations. Cancer Res 65: 1994-2000, 2005.
57. Singer G, Oldt R 3rd, Cohen Y et al: Mutations in BRAF and KRAS characterize the development of low-grade ovarian serous carcinoma. J Natl Cancer Inst 95: 484-486, 2003.
58. Forbes SA, Bhamra G, Bamford S et al: The Catalogue of Somatic Mutations in Cancer (COSMIC). Curr Protoc Hum Genet Chapter 10: Unit 10 1, 2008.
59. Forbes SA, Bindal N, Bamford S et al: COSMIC: mining complete cancer genomes in the Catalogue of Somatic Mutations in Cancer. Nucleic Acids Res 39: 945-950, 2011.
60. Sieben NL, Macropoulos P, Roemen GM et al: In ovarian neoplasms, BRAF, but not KRAS, mutations are restricted to low-grade serous tumours. J Pathol 202: 336-340, 2004.
61. Nakayama N, Nakayama K, Yeasmin S et al: KRAS or BRAF mutation status is a useful predictor of sensitivity to MEK inhibition in ovarian cancer. Br J Cancer 99: 2020-2028, 2008.
62. Farley J, Brady WE, Vathipadiekal V et al: Selumetinib in women with recurrent low-grade serous carcinoma of the ovary or peritoneum: an open-label, single-Arm, phase II study. Lancet Oncol 14: 134-140, 2013.
63. ClinicalTrials.gov Identifier: NCT01849874.
64. ClinicalTrials.gov Identifier: NCT01155453.
65. Chapman PB, Hauschild A, Robert C et al: Updated overall survival (OS) results for BRIM-3, a phase III randomized, open-label, multicenter trial comparing BRAF inhibitor vemurafenib (vem) with dacarbazine (DTIC) in previously untreated patients with BRAFV600E-mutated melanoma. J Clin Oncol 2012; ASCO Annual Meeting Proceedings (Post-Meeting Edition).Vol 30, No 15-suppl (May 20 Supplement) 8502, 2012.
66. http://public.ukcrn.org.uk/search/StudyDetail.aspx?StudyID= 12071. The UK Clinical Research Network Study Portfolio.
67. Chan JK, Teoh D, Hu JM et al: Do clear cell ovarian carcinomas have poorer prognosis compared to other epithelial cell types? A study of 1411 clear cell ovarian cancers. Gynecol Oncol 109(3): 370-376, 2008.
68. Kuo KT, Mao TL, Jones S et al: Frequent activating mutations of PIK3CA in ovarian clear cell carcinoma. Am J Pathol 174(5): 1597-1601, 2009.
69. Hashiguchi Y, Tsuda H, Inoue T et al: PTEN expression in clear cell adenocarcinoma of the ovary. Gynecol Oncol 101(1): 71-75, 2006.
70. Yamashita Y, Akatsuka S, Shinjo K et al: MET is the most frequently amplified gene in endometriosis-Associated ovarian clear cell adenocarcinoma and correlates with worsened prognosis. PLoS One 8(3): e57724, 2013.
71. ClinicalTrials.gov Identifier: NCT01196429.
72. Stany MP, Vathipadiekal V, Ozbun L et al: Identification of novel therapeutic targets in microdissected clear cell ovarian cancers. PLoS One 6(7): e21121, 2011.
73. ClinicalTrials.gov Identifier: NCT00979992.
74. Winter WE 3rd, Maxwell GL, Tian C et al: Prognostic factors for stage III epithelial ovarian cancer: a Gynecologic Oncology Group Study. J Clin Oncol 25: 3621-3627, 2007.
75. Anglesio MS, Kommoss S, Tolcher M et al: Molecular characterization of mucinous ovarian tumors supports a stratified treatment approach with HER2 targeting in 19% of carcinomas. J Pathol 229(1): 111-120, 2013.
76. McAlpine JN, Wiegand KC, Vang R et al: HER2 overexpression and amplification is present in a subset of ovarian mucinous carcinomas and can be targeted with trastuzumab therapy. BMC Cancer 9: 433, 2009.
77. Bookman MA, Darcy KM, Clarke-Pearson D et al: Evaluation of monoclonal humanized anti-HER2 antibody, trastuzumab, in patients with recurrent or refractory ovarian or primary peritoneal carcinoma with overexpression of HER2: a phase II trial of the Gynecologic Oncology Group. J Clin Oncol 21(2): 283-290, 2003.